JP2003528810A - メラノコルチン−4受容体結合化合物及びその使用方法 - Google Patents

メラノコルチン−4受容体結合化合物及びその使用方法

Info

Publication number
JP2003528810A
JP2003528810A JP2001515309A JP2001515309A JP2003528810A JP 2003528810 A JP2003528810 A JP 2003528810A JP 2001515309 A JP2001515309 A JP 2001515309A JP 2001515309 A JP2001515309 A JP 2001515309A JP 2003528810 A JP2003528810 A JP 2003528810A
Authority
JP
Japan
Prior art keywords
phenyl
methoxy
tetrahydro
pyrimidine
benzylsulfanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001515309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528810A5 (enExample
Inventor
マーティン ピー マグワイア
ミンシ ダイ
トリシア ジェイ ヴォス
Original Assignee
ミレニアム ファーマスーティカルズ インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミレニアム ファーマスーティカルズ インク filed Critical ミレニアム ファーマスーティカルズ インク
Publication of JP2003528810A publication Critical patent/JP2003528810A/ja
Publication of JP2003528810A5 publication Critical patent/JP2003528810A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001515309A 1999-08-04 2000-08-04 メラノコルチン−4受容体結合化合物及びその使用方法 Pending JP2003528810A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14728899P 1999-08-04 1999-08-04
US22327700P 2000-08-03 2000-08-03
US60/147,288 2000-08-03
US60/223,277 2000-08-03
PCT/US2000/021327 WO2001010842A2 (en) 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2003528810A true JP2003528810A (ja) 2003-09-30
JP2003528810A5 JP2003528810A5 (enExample) 2007-09-20

Family

ID=26844785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001515309A Pending JP2003528810A (ja) 1999-08-04 2000-08-04 メラノコルチン−4受容体結合化合物及びその使用方法

Country Status (7)

Country Link
EP (1) EP1204645A2 (enExample)
JP (1) JP2003528810A (enExample)
AU (1) AU6621600A (enExample)
BR (1) BR0012984A (enExample)
CA (1) CA2381008A1 (enExample)
MX (1) MXPA02001160A (enExample)
WO (1) WO2001010842A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509014A (ja) * 2002-12-04 2006-03-16 ジーン ロジック インコーポレイテッド メラノコルチンレセプターの調節因子
JP2009509912A (ja) * 2005-06-03 2009-03-12 アミカス セラピューティックス インコーポレイテッド 肥満を治療するための薬理学的シャぺロン
JP2011514371A (ja) * 2008-03-18 2011-05-06 サンセラ ファーマシューティカルズ (シュバイツ) アーゲー メラノコルチン−4受容体モジュレーターとしてのイミダゾピリミジン、イミダゾピラジン及びイミダゾピリダジン誘導体
JP2022508523A (ja) * 2018-10-01 2022-01-19 ジェンザイム・コーポレーション UDPグリコシルトランスフェラーゼ阻害剤としてのチエノ[3,2-b]ピリジン誘導体および使用の方法
KR102903997B1 (ko) 2018-10-01 2025-12-26 젠자임 코포레이션 UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
AU766191B2 (en) 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
CA2405690A1 (en) 2000-04-14 2002-10-09 Kureha Chemical Industry Company, Limited Nitrogen-containing compounds and antiviral drugs containing the same
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
US20040039044A1 (en) * 2000-10-30 2004-02-26 Yuanjin Rui Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
CN1486302A (zh) * 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
WO2002062766A2 (en) * 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
WO2003055873A1 (en) 2001-12-21 2003-07-10 H. Lundbeck A/S Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
AU2003216274A1 (en) * 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
AU2003223049A1 (en) 2002-03-13 2003-09-22 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
DE60333937D1 (de) 2002-05-23 2010-10-07 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
US7396930B2 (en) 2002-06-11 2008-07-08 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
JP2004067673A (ja) * 2002-06-11 2004-03-04 Sankyo Co Ltd 環状チオエーテル類の製造法及びその合成中間体
WO2003104240A1 (ja) * 2002-06-11 2003-12-18 三共株式会社 環状チオエーテル類の製造法及びその合成中間体
GB2389581A (en) * 2002-06-12 2003-12-17 Viaxxel Biotech Gmbh Hydrogenated pyrimidines and their use as inhibitors of deoxyhypusine-synthase or hypusination of eIF-5A
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
JP3714948B2 (ja) 2002-09-11 2005-11-09 呉羽化学工業株式会社 アミン化合物及びその用途
CA2503844A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
FR2852957B1 (fr) * 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
DK1626720T3 (da) 2003-04-04 2008-12-01 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP2007501861A (ja) 2003-05-23 2007-02-01 カイロン コーポレイション Mc4−rアゴニストとしてのグアニジノ置換キナゾリノン化合物
US7368453B2 (en) 2003-11-19 2008-05-06 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
JP4090491B2 (ja) 2003-12-23 2008-05-28 ハー・ルンドベック・アクチエゼルスカベット 2−(1h−インドリルスルファニル)−ベンジルアミン誘導体
CA2558600C (en) 2004-03-10 2013-07-09 Kureha Corporation A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
EA020017B1 (ru) 2009-04-30 2014-08-29 Новартис Аг Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2899954A1 (en) 2013-02-04 2014-08-07 Merck Patent Gmbh Positive allosteric modulators of mglur3
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016056606A1 (ja) * 2014-10-07 2016-04-14 国立大学法人京都大学 ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
TN2019000290A1 (en) 2017-03-20 2021-05-07 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
CN108084109A (zh) * 2017-12-21 2018-05-29 南京工业大学 一种2,5-二取代-1.3.4-噁二唑的合成方法
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
EP3853234B1 (en) 2018-09-18 2025-04-23 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼrの活性化
BR112022004715A2 (pt) 2019-09-19 2022-06-14 Forma Therapeutics Inc Composições de ativação de piruvato quinase r (pkr)
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3171648A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
PL4323362T3 (pl) 2021-04-16 2025-08-18 Gilead Sciences, Inc. Sposoby wytwarzania karbanukleozydów z zastosowaniem amidów
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
JPS4920171A (enExample) * 1972-04-22 1974-02-22
US4122263A (en) * 1973-04-11 1978-10-24 Basf Aktiengesellschaft Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides
JPS57122085A (en) * 1980-12-09 1982-07-29 Bayer Ag Circulatory disease extirpenter and use
JPS6354369A (ja) * 1986-08-15 1988-03-08 Fujisawa Pharmaceut Co Ltd イミダゾ−ル誘導体
JPS63253073A (ja) * 1987-04-08 1988-10-20 Taisho Pharmaceut Co Ltd 2−フエニルベンズイミダゾ−ル誘導体
JPH05148197A (ja) * 1991-05-29 1993-06-15 Akzo Nv フエノキシフエニル誘導体
JPH09176871A (ja) * 1995-12-25 1997-07-08 Tamura Kaken Kk 水溶性プリフラックス、プリント回路基板及びプリント回路基板の金属の表面処理方法
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
WO1998046243A2 (en) * 1997-04-15 1998-10-22 Csir Pharmaceutical compositions having appetite suppressant activity
WO1999032482A1 (en) * 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
JP2002517444A (ja) * 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としてのスピロピペリジン誘導体

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
JPS4920171A (enExample) * 1972-04-22 1974-02-22
US4122263A (en) * 1973-04-11 1978-10-24 Basf Aktiengesellschaft Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides
JPS57122085A (en) * 1980-12-09 1982-07-29 Bayer Ag Circulatory disease extirpenter and use
JPS6354369A (ja) * 1986-08-15 1988-03-08 Fujisawa Pharmaceut Co Ltd イミダゾ−ル誘導体
JPS63253073A (ja) * 1987-04-08 1988-10-20 Taisho Pharmaceut Co Ltd 2−フエニルベンズイミダゾ−ル誘導体
JPH05148197A (ja) * 1991-05-29 1993-06-15 Akzo Nv フエノキシフエニル誘導体
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
JPH09176871A (ja) * 1995-12-25 1997-07-08 Tamura Kaken Kk 水溶性プリフラックス、プリント回路基板及びプリント回路基板の金属の表面処理方法
WO1998046243A2 (en) * 1997-04-15 1998-10-22 Csir Pharmaceutical compositions having appetite suppressant activity
WO1999032482A1 (en) * 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509014A (ja) * 2002-12-04 2006-03-16 ジーン ロジック インコーポレイテッド メラノコルチンレセプターの調節因子
JP2009509912A (ja) * 2005-06-03 2009-03-12 アミカス セラピューティックス インコーポレイテッド 肥満を治療するための薬理学的シャぺロン
JP2013067626A (ja) * 2005-06-03 2013-04-18 Amicus Therapeutics Inc 肥満を治療するための薬理学的シャペロン
JP2011514371A (ja) * 2008-03-18 2011-05-06 サンセラ ファーマシューティカルズ (シュバイツ) アーゲー メラノコルチン−4受容体モジュレーターとしてのイミダゾピリミジン、イミダゾピラジン及びイミダゾピリダジン誘導体
JP2022508523A (ja) * 2018-10-01 2022-01-19 ジェンザイム・コーポレーション UDPグリコシルトランスフェラーゼ阻害剤としてのチエノ[3,2-b]ピリジン誘導体および使用の方法
JP7545979B2 (ja) 2018-10-01 2024-09-05 ジェンザイム・コーポレーション UDPグリコシルトランスフェラーゼ阻害剤としてのチエノ[3,2-b]ピリジン誘導体および使用の方法
KR102903997B1 (ko) 2018-10-01 2025-12-26 젠자임 코포레이션 UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법

Also Published As

Publication number Publication date
BR0012984A (pt) 2002-07-16
WO2001010842A3 (en) 2001-08-16
MXPA02001160A (es) 2002-07-02
CA2381008A1 (en) 2001-02-15
WO2001010842A2 (en) 2001-02-15
AU6621600A (en) 2001-03-05
EP1204645A2 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
JP2003528810A (ja) メラノコルチン−4受容体結合化合物及びその使用方法
EP1644337B1 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
US6699873B1 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
EP1363890A2 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
TWI499416B (zh) 作為crth2拮抗劑之吡唑化合物
AU679049B2 (en) Antipsychotic benzimidazole derivatives
JP3466265B2 (ja) ベンゾイミダゾール化合物及び中枢神経系疾患治療薬
EP1261601B1 (de) Substituierte indole zur modulierung von nfkb-aktivität
JPH01146882A (ja) 治療用複素環化合物
CA2373921A1 (en) Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
JP2001502675A (ja) 1―フエニル―ベンズイミダゾール化合物及びこれをbaga▲下a▼―レセプターモデュレーターとして使用する方法
EP1487821A1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
JPWO2002002533A1 (ja) プロパン−1,3−ジオン誘導体
JP2006509014A (ja) メラノコルチンレセプターの調節因子
BG63257B1 (bg) Заместени пиримидинови съединения и тяхното използване
US20230374143A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss
CA2741500A1 (en) Carbamate compound or salt thereof
WO1999038849A1 (en) PHENYLPIPERAZINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
EP1171435A2 (de) Pyrimidin-2-on derivate als integrinrezeptorliganden
JPH05221989A (ja) 複素環式化合物
CN101166529B (zh) 作为大麻素受体拮抗剂的苯并三唑衍生物
US7030122B2 (en) 1,4-disubstituted piperazine ligands for neurotransmitter receptors
AU2004202804B2 (en) Melanocortin-4 Receptor Binding Compounds and Methods of use thereof
JP2002205987A (ja) アシルアミノシクロプロパン誘導体
CN1938281A (zh) 离子通道调节剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110719